Subcutaneous RYBREVANT®▼ (amivantamab) approved by European Commission for every-three-week and every-four-week dosing for patients with advanced EGFR-mutated non-small cell lung cancer

European regulators have expanded the approval for Johnson & Johnson’s lung cancer treatment, RYBREVANT^® (amivantamab), to include new, more convenient subcutaneous (SC) dosing options. This decision, announced February 23, 2026, allows for the use of RYBREVANT via injection for all previously approved indications, offering patients greater flexibility in how they receive the medication.

Expanding Treatment Options for NSCLC

The European Commission (EC) approval now encompasses both every-four-week (Q4W) and every-three-week (Q3W) SC dosing regimens. These options are applicable to patients with advanced non-small cell lung cancer (NSCLC) harboring specific epidermal growth factor receptor (EGFR) mutations. Specifically, the Q4W regimen is approved for use in combination with LAZCLUZE^® (lazertinib) as a first-line treatment for patients with EGFR exon 19 deletions or exon 21 L858R substitution mutations, and as monotherapy for those with activating EGFR exon 20 insertion mutations after prior platinum-based therapy.

Did You Know? Lung cancer is Europe’s biggest cancer killer, causing more deaths than breast cancer and prostate cancer combined, with an estimated 484,306 diagnoses in 2022.

The Q3W SC regimen is approved in combination with carboplatin and pemetrexed for patients with EGFR exon 19 deletions or exon 21 L858R substitution mutations following prior therapy, including an EGFR tyrosine kinase inhibitor (TKI), and as a first-line treatment for those with activating EGFR exon 20 insertion mutations.

Reduced Treatment Burden

According to Dr. Silvia Novello, Professor of Medical Oncology at San Luigi Hospital in Turin, Italy, the new SC dosing options represent a significant advancement. “Having the option to transition from every-two-week to every-four-week dosing allows us to better align treatment with individual patient needs,” she stated. The SC administration also offers practical benefits, including reduced time spent at the clinic and a lower incidence of administration-related reactions.

Clinical trials, including the Phase 2 PALOMA-2 and Phase 1 PALOMA studies, demonstrated that SC amivantamab maintains efficacy and safety comparable to the intravenous (IV) formulation. Notably, administration time is significantly reduced – approximately five minutes for SC versus five hours for the initial IV infusion.

Expert Insight: The shift towards subcutaneous administration highlights a broader trend in oncology to prioritize patient convenience and reduce the logistical challenges associated with frequent clinic visits. This could lead to improved adherence to treatment plans and a better overall quality of life for patients.

Johnson & Johnson’s Commitment

Henar Hevia, Ph.D., Senior Director at Johnson & Johnson Innovative Medicine, emphasized the company’s dedication to improving the treatment journey for patients with EGFR-mutated NSCLC. The approval of these new regimens, she stated, aims to reduce the burden of treatment on both patients and their caregivers while preserving the established effectiveness of intravenous amivantamab.

Frequently Asked Questions

What types of NSCLC are these new dosing options for?

The new SC dosing regimens are for adult patients with advanced NSCLC with activating EGFR exon 19 deletions, exon 21 L858R substitution mutations, or activating EGFR exon 20 insertion mutations, depending on the specific regimen and prior treatments.

What is the difference between the Q4W and Q3W regimens?

The Q4W regimen involves administering amivantamab every four weeks, while the Q3W regimen involves administration every three weeks. Both are subcutaneous injections and are approved for different combinations and lines of therapy.

What are the most common side effects associated with amivantamab?

Consistent with the IV formulation, the most common treatment-emergent adverse events (TEAEs) were EGFR- and MET-related, including dermatitis acneiform, paronychia, rash, stomatitis, and hypoalbuminemia.

Looking ahead, the wider availability of SC amivantamab could lead to increased adoption of this treatment option, potentially improving outcomes for patients with EGFR-mutated NSCLC. Further real-world data will be crucial to assess the long-term impact of these new dosing regimens on patient care and quality of life.

How might increased convenience in cancer treatment impact patient adherence and overall outcomes?